IRCT20200105046010N104招募中Unknown
In-vivo Bioequivalence Study of Montelukast 5 mg chewable tablets and 10 mg FC. tablets (Faran Shimi, Iran) With Brand Drug (SINGULAIR® 5 mg chewable Tab. & 10 mg FC Tab., MSD Pharma, Germany) in Iranian Healthy Volunteers
Pharan shimi Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index 18-28 kg/m^2
- •consentAge of 18-55 years old
- •Informed consent
排除标准
- •Nicotine consumption
- •history Cardiovascular disease
- •History Liver and kidney
- •HistoryAlcohol and opioid addiction
- •Allergy reactions history to Montelukast
研究者
相似试验
尚未招募
Unknown
Bioequivalence evaluation of Montelukast 4 mg granule of Actover Pharmaceutical companyIRCT20200625047913N17Hezareh Sevom Futuristic Pharmacist24
已完成
3 期
Evaluation of montelukast efficacy on clinical and FEV1/PEFR improvement in acute basthma attackAcute attack asthma.AsthmaIRCT2015092215446N5Vice chanceller for research, Ahvaz Jundishapur University of Medical Sciences80
尚未招募
1 期
A Bioequivalence Study of 5-mg Montelukast Sodium Chewable Tablets in Healthy Thai Volunteers under Fasting ConditioHealthy volunteersBioequivalenceMontelukastTCTR20170516004T.O. Chemicals (1979) Ltd.26
招募中
3 期
The effect of Montelukast on COVID 19 disease activityIRCT20181208041886N3Abidi Pharmaceutical company60
已完成
3 期
Therapeutic effect of Montelukast in patients with oral lichen planusLichen Planusichen Planus.IRCT2012110811389N2Vice Chancellor for Research , Hamedan University of Medical Sciences200